<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ferumoxytol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ferumoxytol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ferumoxytol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12211" href="/d/html/12211.html" rel="external">see "Ferumoxytol: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="142554" href="/d/html/142554.html" rel="external">see "Ferumoxytol: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F27640154"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious hypersensitivity/anaphylaxis reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fatal and serious hypersensitivity reactions including anaphylaxis have occurred in patients receiving ferumoxytol. Initial symptoms may include hypotension, syncope, unresponsiveness, cardiac/cardiorespiratory arrest.</p>
<p style="text-indent:-2em;margin-left:2em;">Only administer ferumoxytol as an intravenous infusion over at least 15 minutes and only when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">Observe for signs or symptoms of hypersensitivity reactions during and for at least 30 minutes following ferumoxytol infusion including monitoring of blood pressure and pulse during and after administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions have occurred in patients in whom a previous ferumoxytol dose was tolerated.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F7890587"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Feraheme</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F7897720"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Iron Preparations</li></ul></div>
<div class="block doa drugH1Div" id="F7897833"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b>
<b>Route of administration: </b>IV iron replacement is preferred over oral replacement in several clinical situations (eg, poor GI absorption, lack of response to or poor tolerability of oral iron, need for rapid repletion, chronic kidney disease, active inflammatory bowel disease, cancer, chronic or extensive blood loss) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Auerbach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Auerbach.1'])">Ref</a></span>). <b>Dosage expression: </b>Dose is expressed in mg of elemental iron. <b>Test dose: </b>A test dose is not required<b>.</b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="035e1654-7eac-49da-83bd-23b3e0ca305a">Iron-deficiency anemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-dose regimen:</i>
<b>IV:</b> 1.02 g as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23828252','lexi-content-ref-31155744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23828252','lexi-content-ref-31155744'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Two-dose regimen:</i>
<b>IV:</b> 510 mg once; after 3 to 8 days, administer a second dose of 510 mg once.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a27bf4fa-d927-4d4d-9129-926375dd3e9b">Magnetic resonance imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Magnetic resonance imaging (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consider for use as an alternative to gadolinium-based contrast agents.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>Usual dosage range: 2 to 5 mg/kg; maximum reported dose: 510 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33098154','lexi-content-ref-29731126','lexi-content-ref-31638489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33098154','lexi-content-ref-29731126','lexi-content-ref-31638489'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991470"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary. </p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Not removed by hemodialysis; however, administer dose after at least 1 hour of hemodialysis has been completed and once blood pressure has stabilized.</p></div>
<div class="block doha drugH1Div" id="F50988806"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F7897834"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F58591763"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="142554" href="/d/html/142554.html" rel="external">see "Ferumoxytol: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose is expressed in mg of elemental iron.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a27bf4fa-d927-4d4d-9129-926375dd3e9b">Magnetic resonance imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Magnetic resonance imaging:</b> Limited data available: Infants, Children, and Adolescents: IV: Usual dosage range: 3 to 5 mg/kg/dose as a single dose; reported range: 1 to 11 mg/kg/dose; maximum reported dose: 510 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36197052','lexi-content-ref-32930651','lexi-content-ref-26656202','lexi-content-ref-31638489','lexi-content-ref-36999999','lexi-content-ref-25427433','lexi-content-ref-29848399']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36197052','lexi-content-ref-32930651','lexi-content-ref-26656202','lexi-content-ref-31638489','lexi-content-ref-36999999','lexi-content-ref-25427433','lexi-content-ref-29848399'])">Ref</a></span>). Dose may vary by type of imaging; the following has been suggested: 3 mg/kg for cardiac MRI and 5 mg/kg for oncologic MRI for adequate tissue enhancement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36197052','lexi-content-ref-36999999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36197052','lexi-content-ref-36999999'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F58591769"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Magnetic resonance imaging:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;4 years: Mild to severe impairment: There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; there is no data available for this indication.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Mild to moderate impairment: There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; there is no data available for this indication.</p>
<p style="text-indent:-2em;margin-left:8em;">Severe impairment: There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; based on a pediatric cohort study, no dosage adjustment needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25212105']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25212105'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis:</b> Not removed by hemodialysis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Magnetic resonance imaging:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;4 years: There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; there is no data available for this indication.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents: There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; based on a pediatric cohort study, no dosage adjustment needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25212105']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25212105'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F7897766"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (1%), edema (2%), hypertension (1%), hypotension (≤3%), peripheral edema (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (1%), skin rash (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (1%), constipation (2%), diarrhea (1% to 4%), nausea (2% to 3%), vomiting (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (≤4%; severe hypersensitivity reaction: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (3%), fatigue (2%), headache (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (1%), muscle spasm (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (1%), dyspnea (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, flushing</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastroenteritis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acute posthemorrhagic anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, heart failure, ischemic heart disease, syncope, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Loss of consciousness, unresponsive to stimuli</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cyanosis</p></div>
<div class="block coi drugH1Div" id="F7897763"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to ferumoxytol, other IV iron products, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F7897764"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: <b>[US Boxed Warning]: Serious hypersensitivity reactions, (some fatal), including anaphylaxis may occur, presenting with cardiac/cardiorespiratory arrest, clinically significant hypotension, syncope, or unresponsiveness even in patients who previously tolerated ferumoxytol. Infuse over ≥15 minutes and have equipment for resuscitation and trained personnel experienced in handling emergencies immediately available during use. Monitor patients for signs/symptoms of hypersensitivity reactions, including blood pressure and pulse during and ≥30 minutes (until clinically stable) following administration. </b> Other hypersensitivity reactions have also occurred (pruritus, rash, urticaria, wheezing). Patients with multiple drug allergies may have greater risk of anaphylaxis; elderly patients with multiple or serious comorbidities who develop hypersensitivity and/or hypotension after ferumoxytol may be at greater risk for serious adverse events.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Hypotension, including serious hypotensive reactions, may occur; monitor patients for hypotension following administration.</p>
<p style="text-indent:0em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Do not administer in the presence of tissue iron overload; periodic monitoring of hemoglobin, serum ferritin, serum iron, and transferrin saturation is recommended. Serum iron and transferrin-bound iron may be overestimated in laboratory assays if level is drawn during the first 24 hours following administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Magnetic resonance imaging: Administration may alter MRI; conduct anticipated MRI studies prior to use if using for iron repletion. MRI alterations may persist for ≤3 months following use, with peak alterations anticipated in the first 2 days following administration. If MRI is required within 3 months after administration, use T1- or proton density-weighted magnetic resonance pulse sequences to decrease effect on imaging. Do not use T2-weighted sequence MRI prior to 4 weeks following ferumoxytol administration. Ferumoxytol does not interfere with X-ray, computed tomography (CT), positron emission tomography (PET), single photon emission computed tomography (SPECT), ultrasound or nuclear medicine imaging.</p></div>
<div class="block dosfc drugH1Div" id="F21963472"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Strength of ferumoxytol is expressed as elemental iron</p></div>
<div class="block foc drugH1Div" id="F7897839"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Feraheme: 510 mg/17 mL (17 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 510 mg/17 mL (17 mL)</p></div>
<div class="block geq drugH1Div" id="F7897718"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322355"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Feraheme Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">510 mg/17 mL (per mL): $81.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ferumoxytol Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">510 mg/17 mL (per mL): $63.91</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F7897835"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer each 510 mg dose diluted as a slow IV infusion over at least 15 minutes. When administering as a single dose (ie, 1.02 g), administer over ~30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23828252','lexi-content-ref-31155744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23828252','lexi-content-ref-31155744'])">Ref</a></span>). Patient should be in a reclined or semi-reclined position during the infusion; monitor for signs of hypersensitivity (including BP and pulse) for at least 30 minutes after infusion. Also refer to institution-specific protocols. <b>Note:</b> Serious hypersensitivity reactions have been observed with rapid IV injection (&lt;1 minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24458078','lexi-content-ref-23983177']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24458078','lexi-content-ref-23983177'])">Ref</a></span>). Wait ≥30 minutes between administration of ferumoxytol and other agents that may cause serious hypersensitivity reactions and/or hypotension (eg, chemotherapy, monoclonal antibodies).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis patients: Administer dose after at least 1 hour of hemodialysis has been completed and once BP has stabilized.</p></div>
<div class="block admp drugH1Div" id="F58591771"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: <b>Magnetic resonance imaging: </b>Administration practice may vary with type of imaging being performed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26890830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26890830'])">Ref</a></span>). In adults, serious hypersensitivity reactions have been observed with rapid IV injection (&lt;1 minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24458078','lexi-content-ref-23983177']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24458078','lexi-content-ref-23983177'])">Ref</a></span>); consider waiting ≥30 minutes between administration of ferumoxytol and other agents that may cause serious hypersensitivity reactions and/or hypotension (eg, chemotherapy, monoclonal antibodies).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Administration as a diluted solution IV over 5 to 15 minutes has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27678106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27678106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Administer as a diluted solution over ≥15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36197052','lexi-content-ref-31638489','lexi-content-ref-36999999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36197052','lexi-content-ref-31638489','lexi-content-ref-36999999'])">Ref</a></span>). In a cardiac MRI trial (n=61) performed under general anesthesia, ferumoxytol was infused over 5 to 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29848399']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29848399'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F7897722"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Iron-deficiency anemia: </b>Treatment of iron-deficiency anemia in adults with an intolerance or unsatisfactory response to oral iron or who have chronic kidney disease</p></div>
<div class="block off-label drugH1Div" id="F56709475"><span class="drugH1">Use: Off-Label: Adult</span><p>Magnetic resonance imaging</p></div>
<div class="block mst drugH1Div" id="F7897717"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ferumoxytol may be confused with ferric carboxymaltose, ferric gluconate, iron dextran complex, iron sucrose</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299328"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F7907577"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Dimercaprol: May enhance the nephrotoxic effect of Iron Preparations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Iron Preparations may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F7897724"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Iron transfer to the fetus is regulated by the placenta (BSH [Pavord 2020]; NAS 2020).</p>
<p style="text-indent:0em;margin-top:2em;">There is a risk of adverse maternal reactions (eg, anaphylaxis, hypotension, shock) following use of parenteral iron, which may result in fetal bradycardia, especially during the second and third trimesters. Although the risk is rare, immediate treatment for anaphylactoid and/or hypersensitivity reactions should be available (BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal iron requirements increase during pregnancy. Untreated iron deficiency and iron deficiency anemia (IDA) in pregnant patients are associated with adverse pregnancy outcomes, including low birth weight, preterm birth, and increased perinatal mortality (ACOG 2021; BSH [Pavord 2020]). Maternal iron deficiency is also associated with fatigue, increased risk of postpartum depression, and possibly postpartum hemorrhage (BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Oral and parenteral iron are effective at replacing iron stores in pregnant patients (ACOG 2021). Most studies note iron therapy improves maternal hematologic parameters; however, data related to clinical outcomes in the mother and neonate are limited (FIGO 2019; NAS 2020; USPSTF [Siu 2015]). Parenteral iron therapy may be used in pregnant patients who cannot tolerate or respond to oral iron, when iron deficiency occurs later in pregnancy, or when malabsorption is present (ACOG 2021; BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Ferumoxytol has been evaluated in pregnant patients with IDA (Gerb 2021; Karki 2019). Due to limited safety data in early pregnancy, use of IV iron is generally not started until the second or third trimester (ACOG 2021; BSH [Pavord 2020]; FIGO 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Ferumoxytol has been evaluated for use as an alternative to gadolinium-based contrast agents in patients undergoing an MRI; this use is not currently recommended in pregnant patients (ACOG 2017; Little 2020).</p></div>
<div class="block brc drugH1Div" id="F7897727"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Iron is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Endogenous iron concentrations in breast milk vary by postpartum age and are lower than concentrations in the maternal plasma (Dorea 2000; Emmett 1997). Breast milk concentrations of iron are maintained in lactating patients with mild to moderate iron deficiency anemia (IDA), but concentrations decrease if IDA is moderate to severe (El-Farrash 2012) or severe (Kumar 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">Iron deficiency and IDA are associated with adverse effects in postpartum patients (eg, altered cognition, depression, fatigue), which may influence interactions with the infant. Iron supplementation in the postpartum patient should be initiated as soon as possible following delivery when gestational anemia is a concern (WHO 2016). Parenteral iron therapy may be used in postpartum patients with uncorrected anemia at delivery who cannot tolerate, do not respond to, or are noncompliant with oral iron therapy, or the severity of anemia requires prompt management (BSH [Pavord 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F7897837"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hemoglobin, serum ferritin, serum iron, transferrin saturation (at least 1 month following second injection and periodically); signs/symptoms of hypersensitivity reactions, blood pressure, pulse (during and ≥30 minutes following administration)</p></div>
<div class="block rer drugH1Div" id="F7897809"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Hemoglobin, whole blood:</p>
<p style="text-indent:-2em;margin-left:6em;">Female: 12 to16 g/dL (SI: 120 to 160 g/L) (ABIM 2023).</p>
<p style="text-indent:-2em;margin-left:6em;">Male: 13 to 18 g/dL (SI: 130 to 180 g/L) (ABIM 2023; WHO 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron deficiency (ABIM 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Ferritin, serum: <b>Note:</b> Ferritin is an acute phase reactant; levels may be elevated in the presence of inflammation or infection which is independent of iron status (WHO 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">Female: 24 to 307 ng/mL (SI: 53.9 to 689.8 picomole/L).</p>
<p style="text-indent:-2em;margin-left:6em;">Male: 24 to 336 ng/mL (SI: 53.9 to 755 picomole/L).</p>
<p style="text-indent:-2em;margin-left:4em;">Iron, serum: 50 to 150 mcg/dL (SI: 9 to 26.9 micromole/L).</p>
<p style="text-indent:-2em;margin-left:4em;">Total iron binding capacity, serum: 250 to 310 mcg/dL (SI: 44.8 to 55.5 micromole/L).</p>
<p style="text-indent:-2em;margin-left:4em;">Transferrin saturation: 20% to 50%.</p>
<p style="text-indent:-2em;margin-left:4em;">Transferrin, serum: 200 to 400 mg/dL (SI: 24.6 to 49.2 micromole/L).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic kidney disease–associated anemia:</b> To achieve and maintain target hemoglobin for patients with nondialysis-dependent chronic kidney disease, patients with a transferrin saturation (TSAT) ≤30% and a serum ferritin level ≤500 ng/mL (SI: 1,123.5 picomole/L) will often respond to iron supplementation (Gutiérrez 2021; KDIGO 2012).</p></div>
<div class="block pha drugH1Div" id="F7897807"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Superparamagnetic iron oxide coated with a low molecular weight semisynthetic carbohydrate; iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow where the iron is released from the complex. The released iron is either transported into storage pools or is transported via plasma transferrin for incorporation into hemoglobin. </p></div>
<div class="block phk drugH1Div" id="F7897810"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 3.16 L</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Iron released from iron-carbohydrate complex after uptake in the reticuloendothelial system macrophages of the liver, spleen, and bone marrow</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~15 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Dialysis: Ferumoxytol is not removed by hemodialysis</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059483"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Rienso</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Rienso</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Rienso</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Rienso</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Rienso</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Rienso</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Rienso</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Rienso</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Rienso</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Feraheme</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Rienso</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Rienso</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-36197052">
<a name="36197052"></a>Adams LC, Jayapal P, Ramasamy SK, et al. Ferumoxytol-enhanced MRI in children and young adults: state of the art. <i>AJR Am J Roentgenol</i>. 2023;220(4):590-603. doi:10.2214/AJR.22.28453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/36197052/pubmed" id="36197052" target="_blank">36197052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33098154">
<a name="33098154"></a>Ahmad F, Treanor L, McGrath TA, Walker D, McInnes MDF, Schieda N. Safety of off-label use of ferumoxtyol as a contrast agent for MRI: a systematic review and meta-analysis of adverse events. <i>J Magn Reson Imaging</i>. 2021;53(3):840-858. doi:10.1002/jmri.27405<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/33098154/pubmed" id="33098154" target="_blank">33098154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ABIM.1">
<a name="ABIM.1"></a>American Board of Internal Medicine (ABIM). Laboratory Test Reference Ranges. <i>Lexi-Drugs</i>. UpToDate Lexidrug. Waltham, MA: UpToDate Inc. https://online.lexi.com. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34293770">
<a name="34293770"></a>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. Anemia in pregnancy: ACOG practice bulletin, number 233. <i>Obstet Gynecol</i>. 2021;138(2):e55-e64. doi:10.1097/AOG.0000000000004477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/34293770/pubmed" id="34293770" target="_blank">34293770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28937575">
<a name="28937575"></a>American College of Obstetricians and Gynecologists (ACOG). Committee opinion no. 723: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2017;130(4):e210-e216. doi:10.1097/AOG.0000000000002355<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/28937575/pubmed" id="28937575" target="_blank">28937575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18971010">
<a name="18971010"></a>Auerbach M, “Ferumoxytol as a New, Safer, Easier-to-Administer Intravenous Iron: Yes or No”, <i>Am J of Kidney Dis</i>, 2008, 52(5):826-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/18971010/pubmed" id="18971010" target="_blank">18971010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Auerbach.1">
<a name="Auerbach.1"></a>Auerbach M. Treatment of iron deficiency anemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23828252">
<a name="23828252"></a>Auerbach M, Strauss W, Auerbach S, Rineer S, Bahrain H. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. <i>Am J Hematol</i>. 2013;88(11):944-947. doi:10.1002/ajh.23534<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/23828252/pubmed" id="23828252" target="_blank">23828252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10705077">
<a name="10705077"></a>Dorea JG. Iron and copper in human milk. <i>Nutrition</i>. 2000;16(3):209-220. doi:10.1016/s0899-9007(99)00287-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/10705077/pubmed" id="10705077" target="_blank">10705077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21548016">
<a name="21548016"></a>El-Farrash RA, Ismail EA, Nada AS. Cord blood iron profile and breast milk micronutrients in maternal iron deficiency anemia. <i>Pediatr Blood Cancer</i>. 2012;58(2):233-238. doi:10.1002/pbc.23184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/21548016/pubmed" id="21548016" target="_blank">21548016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9363415">
<a name="9363415"></a>Emmett PM, Rogers IS. Properties of human milk and their relationship with maternal nutrition. <i>Early Hum Dev</i>. 1997;(49)(suppl):S7-S28. doi:10.1016/s0378-3782(97)00051-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/9363415/pubmed" id="9363415" target="_blank">9363415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feraheme.1">
<a name="Feraheme.1"></a>Feraheme (ferumoxytol) [prescribing information]. Waltham, MA: AMAG Pharmaceuticals, Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30710364">
<a name="30710364"></a>FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine. Good clinical practice advice: iron deficiency anemia in pregnancy. <i>Int J Gynaecol Obstet</i>. 2019;144(3):322-324. doi:10.1002/ijgo.12740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/30710364/pubmed" id="30710364" target="_blank">30710364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34104372">
<a name="34104372"></a>Gerb J, Strauss W, Derman R, et al. Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy. <i>Ther Adv Hematol</i>. 2021;12:20406207211018042. doi:10.1177/20406207211018042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/34104372/pubmed" id="34104372" target="_blank">34104372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34514189">
<a name="34514189"></a>Gutiérrez O. Treatment of iron deficiency anemia in CKD and end-stage kidney disease. <i>Kidney Int Rep. </i>2021;6(9):2261-2269. doi:10.1016/j.ekir.2021.05.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/34514189/pubmed" id="34514189" target="_blank">34514189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32930651">
<a name="32930651"></a>Iv M, Ng NN, Nair S, et al. Brain iron assessment after ferumoxytol-enhanced MRI in children and young adults with arteriovenous malformations: a case-control study. <i>Radiology</i>. 2020;297(2):438-446. doi:10.1148/radiol.2020200378<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/32930651/pubmed" id="32930651" target="_blank">32930651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31155744">
<a name="31155744"></a>Karki NR, Auerbach M. Single total dose infusion of ferumoxytol (1020 mg in 30 minutes) is an improved method of administration of intravenous iron. <i>Am J Hematol</i>. 2019;94(9):E229-E231. doi:10.1002/ajh.25548<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/31155744/pubmed" id="31155744" target="_blank">31155744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for anemia in chronic kidney disease (2012). https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18310187">
<a name="18310187"></a>Kumar A, Rai AK, Basu S, et al. Cord blood and breast milk iron status in maternal anemia. <i>Pediatrics</i>. 2008;121(3):e673-e677. doi:10.1542/peds.2007-1986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/18310187/pubmed" id="18310187" target="_blank">18310187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27678106">
<a name="27678106"></a>Lai LM, Cheng JY, Alley MT, Zhang T, Lustig M, Vasanawala SS. Feasibility of ferumoxytol-enhanced neonatal and young infant cardiac MRI without general anesthesia. <i>J Magn Reson Imaging</i>. 2017;45(5):1407-1418. doi:10.1002/jmri.25482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/27678106/pubmed" id="27678106" target="_blank">27678106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29731126">
<a name="29731126"></a>Lehrman ED, Plotnik AN, Hope T, Saloner D. Ferumoxytol-enhanced MRI in the peripheral vasculature. <i>Clin Radiol.</i> 2019;74(1):37-50. doi:10.1016/j.crad.2018.02.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/29731126/pubmed" id="29731126" target="_blank">29731126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33040992">
<a name="33040992"></a>Little JT, Bookwalter CA. Magnetic resonance safety: pregnancy and lactation. <i>Magn Reson Imaging Clin N Am</i>. 2020;28(4):509-516. doi:10.1016/j.mric.2020.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/33040992/pubmed" id="33040992" target="_blank">33040992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24458078">
<a name="24458078"></a>Macdougall IC, Strauss WE, McLaughlin J, Li Z, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.<i> Clin J Am Soc Nephrol</i>. 2014;9(4):705-712. doi: 10.2215/CJN.05320513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/24458078/pubmed" id="24458078" target="_blank">24458078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26656202">
<a name="26656202"></a>Muehe AM, Feng D, von Eyben R, et al. Safety report of ferumoxytol for magnetic resonance imaging in children and young adults. <i>Invest Radiol</i>. 2016;51(4):221-227. doi:10.1097/RLI.0000000000000230<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/26656202/pubmed" id="26656202" target="_blank">26656202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAS.2020">
<a name="NAS.2020"></a>National Academies of Sciences, Engineering, and Medicine 2020. <i>Nutrition During Pregnancy and Lactation: Exploring New Evidence: Proceedings of a Workshop</i>. The National Academies Press; 2020. https://doi.org/10.17226/25841</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25212105">
<a name="25212105"></a>Nayak AB, Luhar A, Hanudel M, et al. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort. <i>Pediatr Nephrol</i>. 2015;30(3):515-521. doi:10.1007/s00467-014-2953-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/25212105/pubmed" id="25212105" target="_blank">25212105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31638489">
<a name="31638489"></a>Nguyen KL, Yoshida T, Kathuria-Prakash N, et al. Multicenter safety and practice for off-label diagnostic use of ferumoxytol in MRI. <i>Radiology</i>. 2019;293(3):554-564. doi:10.1148/radiol.2019190477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/31638489/pubmed" id="31638489" target="_blank">31638489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31578718">
<a name="31578718"></a>Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J. UK guidelines on the management of iron deficiency in pregnancy. <i>Br J Haematol</i>. 2020;188(6):819-830. doi:10.1111/bjh.16221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/31578718/pubmed" id="31578718" target="_blank">31578718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36999999">
<a name="36999999"></a>Rashidi A, Baratto L, Theruvath AJ, et al. Improved detection of bone metastases in children and young adults with ferumoxytol-enhanced MRI. <i>Radiol Imaging Cancer.</i> 2023;5(2):e220080. doi: 10.1148/rycan.220080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/36999999/pubmed" id="36999999" target="_blank">36999999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25427433">
<a name="25427433"></a>Ruangwattanapaisarn N, Hsiao A, Vasanawala SS. Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children. <i>Pediatr Radiol</i>. 2015;45(6):831-839. doi:10.1007/s00247-014-3226-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/25427433/pubmed" id="25427433" target="_blank">25427433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344176">
<a name="26344176"></a>Siu AL; US Preventive Services Task Force. Screening for iron deficiency anemia and iron supplementation in pregnant women to improve maternal health and birth outcomes: US preventive services task force recommendation statement. <i>Ann Intern Med</i>. 2015;163(7):529-536. doi:10.7326/M15-1707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/26344176/pubmed" id="26344176" target="_blank">26344176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23983177">
<a name="23983177"></a>Vadhan-Raj S, Strauss W, Ford D, et al. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. <i>Am J Hematol</i>. 2014;89(1):7-12. doi: 10.1002/ajh.23582.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/23983177/pubmed" id="23983177" target="_blank">23983177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26890830">
<a name="26890830"></a>Vasanawala SS, Nguyen KL, Hope MD, et al. Safety and technique of ferumoxytol administration for MRI. <i>Magn Reson Med</i>. 2016;75(5):2107-2111. doi:10.1002/mrm.26151<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/26890830/pubmed" id="26890830" target="_blank">26890830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29848399">
<a name="29848399"></a>Wise-Faberowski L, Velasquez N, Chan F, Vasanawala S, McElhinney DB, Ramamoorthy C. Safety of ferumoxytol in children undergoing cardiac MRI under general anaesthesia. <i>Cardiol Young</i>. 2018;28(7):916-921. doi:10.1017/S1047951118000306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/29848399/pubmed" id="29848399" target="_blank">29848399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27583315">
<a name="27583315"></a>World Health Organization (WHO). <i>Guideline: Iron Supplementation in Postpartum Women</i>. World Health Organization; 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferumoxytol-drug-information/abstract-text/27583315/pubmed" id="27583315" target="_blank">27583315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. https://iris.who.int/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf?sequence=22. Published 2011. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Serum ferritin concentrations for the assessment of iron status in individuals and populations: technical brief. https://iris.who.int/bitstream/handle/10665/337666/9789240008526-eng.pdf?sequence=1. Published 2020. Accessed December 11, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9044 Version 187.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
